Enterprise Value to EBITDA Ratio: AON (AONC)
American Oncology Network (AONC) dominates the oncology care segment, leveraging drug procurement volumes to control pricing and support smaller centers. This daily price chart, featuring an EV/EBITDA metric of , confirms the stability of cash flows driven by non-cyclical demand. Business efficiency is increasing as the company outsources IT infrastructure and logistics to third-party contractors, optimizing the company's operational processes.
Metric breakdowns and analytics for American Oncology Network Inc (AONC)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
AONC - Net Financial Result|Projected Future Earnings American Oncology Network|AONC - Price to Earnings Ratio|Forward P/E Multiple American Oncology Network Inc|AONC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AON|AONC - Operating profit before amortization|Net earnings per share for the last 12 months American Oncology Network|AONC - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months aoncology.com|AONC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year American Oncology Network
- company sales and revenue statistics:
Analysis of all company metrics:AON AONC
The EV/EBITDA multiple assesses business value inclusive of net debt relative to operating profit, allowing for the determination of an asset's real value without the influence of taxes and depreciation. This metric discounts market expectations, helping investors identify cyclical shifts in a timely manner through the dynamics of a business's EV/EBITDA ratio. For American Oncology Network (AONC), this confirms the effectiveness of network expansion while maintaining a stable patient flow and rhythmic working capital.
Competitor analysis
BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara Therapeutics (TARA)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (aadibio.com)|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OSTX (OS Therapies Incorporated)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics Ltd|Company Value to EBITDA Artiva Biotherapeutics ARTV|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Company Value to EBITDA|RENB: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Curis, Inc. (CRIS)|EV/EBITDA Multiple APLM|Enterprise Value to Operating Income Before Depreciation Ratio THAR|EV/EBITDA Multiple ADVB (advanbiomed.com)|GNPX - Enterprise Value to EBITDA Ratio|CLDI: Enterprise Value to EBITDA Ratio|SBFM - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLRX: Enterprise Value to Operating Income Before Depreciation Ratio|PPBT (Purple Biotech Ltd) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple
